About laronidase
Lysosomal enzyme replacement therapy
Used for
- Long-term enzyme replacement for mucopolysaccharidosis type I (MPS I).
Usual adult dose
0.58 mg/kg by intravenous infusion once weekly.
Usual dose in children
0.58 mg/kg by intravenous infusion once weekly; used in children with MPS I.
Common side effects
- Infusion reactions, including fever, chills, rash, or breathing difficulty
- Headache
- Abdominal pain, nausea, or vomiting
- Joint pain
Important warnings
- Infusions require medical supervision; severe allergic reactions can occur.
- Breathing problems during infusion may be more likely with airway or lung disease.
- Antibodies may develop and can affect treatment response or infusion reactions.
- Not a cure; it does not reverse established neurological damage.
Pregnancy
Limited human data; use during pregnancy only when clinically necessary after specialist assessment.
Breastfeeding
Unknown whether laronidase passes into breast milk; specialist assessment is recommended.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.